Ketamine has been hailed as a fast-acting, effective treatment for major depression. But new research questions whether the drug lives up to its hype.

Federal regulators fast-tracked approval of psychedelic drugs to treat some of the nation’s most stubborn mental health disorders, reopening a debate that has lingered since the counterculture era: ...

(Guido Mieth/Moment/Getty Images) Around a third of people with major depressive disorder don't respond to standard ...

The anti-inflammatory drug tocilizumab targets the IL-6 pathway to achieve a 54% remission rate in hard-to-treat depression.

Nearly 1 in 5 U.S. adolescents experienced depression between 2021 and 2023, and those teens were significantly more likely to use substances such as alcohol, marijuana and opioids, according to a new ...

A year after the US Food and Drug Administration (FDA) opened the door to clinical use of lysergic acid diethylamide (LSD), US-based MindMed has launched phase 3 trials in the United States and Europe ...

Ketamine therapy offers a new option for treatment-resistant depression. Unlike traditional antidepressants, ketamine acts fast in controlled settings. Generally safe but requires monitoring for short ...

Imagine unremitting despair, 24-7, minimally responsive or totally unresponsive to medication or therapy. Just endless depression. This is a problem for at least a third of adults with depression, ...

Brain-stimulating contact lenses are as effective as Prozac at treating depression in mice via retinal pathways.

-- Reposted from the online magazine, "The Trauma & Mental Health Report" The pharmaceutical industry grosses over $300 billion a year in psychotropic medication sales. Included in this figure are ...